DESCRIPTION OF PROPHYLACTIC DRUG UTILIZATION PATTERNS IN MIGRAINE PATIENTS
Author(s)
Shei A1, Woolley JM2, Desai PR3, Enloe CJ1, Kirson NY1, Birnbaum HG1, Corey-Lisle PK4, Sapra S3
1Analysis Group, Inc., Boston, MA, USA, 2Amgen Inc., South San Francisco, CA, USA, 3Amgen Inc., Thousand Oaks, CA, USA, 4EMD Serono, Inc., Rockland, MA, USA
OBJECTIVES: Describe medication utilization patterns of migraine prophylactics in commercially insured patients. METHODS: Adult migraineurs (ICD-9 code 346.XX) newly initiating migraine prophylactics (no claims for 12 months before first (index) prophylactic prescription) between January 2007 and March 2013 were identified from the OptumInsight employer claims database and followed for 6 months. Prophylactics included antiepileptics (topiramate, divalproex, valproic acid), beta-blockers (propranolol, timolol), antidepressants (amitriptyline) and onabotulinumtoxinA. Continuous enrollment was required for 12 months pre-index and 6 months post-index. To increase the specificity of migraine prophylactics, patients with prior diagnoses for conditions for which their prescribed prophylactics were also indicated (i.e., epilepsy for antiepileptics, hypertension/congestive heart failure for beta-blockers, and depression for amitriptyline) were excluded. Outcomes of interest were medication adherence (medication possession ratio [MPR]), discontinuation (>30-day gap between prescriptions), and switching patterns. Time to discontinuation of initial prophylactic was described using Kaplan-Meier curves. RESULTS:
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PND41
Topic
Patient-Centered Research
Topic Subcategory
Adherence, Persistence, & Compliance
Disease
Neurological Disorders